Compared to NPs with typical MΦM coating, ICG/DOX@AM-NP armed with anti-HER2 affibody demonstrated outstanding HER2-targeting capabilities and exhibited synergistic suppression of HER2+ cancer cells by triggering apoptosis and inhibiting the PI3K/AKT signaling pathway 86. Here, ERBB2 is linked to cancer.